Izicopan
Hidradenitis Suppurativa
Key Facts
About InflaRx
InflaRx is a clinical-stage biopharma focused on selectively inhibiting the C5a/C5aR pathway of the complement system, a key driver of inflammatory diseases. The company achieved a significant milestone with the FDA EUA for vilobelimab in severe COVID-19 and is developing this candidate and its oral C5aR inhibitor, izicopan, across multiple dermatologic and critical care indications. Despite recent clinical setbacks, InflaRx continues to explore the therapeutic potential of its complement platform in life-threatening and debilitating inflammatory conditions.
View full company profileAbout InflaRx
InflaRx is a clinical-stage biopharma focused on selectively inhibiting the C5a/C5aR pathway of the complement system, a key driver of inflammatory diseases. The company achieved a significant milestone with the FDA EUA for vilobelimab in severe COVID-19 and is developing this candidate and its oral C5aR inhibitor, izicopan, across multiple dermatologic and critical care indications. Despite recent clinical setbacks, InflaRx continues to explore the therapeutic potential of its complement platform in life-threatening and debilitating inflammatory conditions.
View full company profileAbout InflaRx
InflaRx is a clinical-stage biopharma focused on selectively inhibiting the C5a/C5aR pathway of the complement system, a key driver of inflammatory diseases. The company achieved a significant milestone with the FDA EUA for vilobelimab in severe COVID-19 and is developing this candidate and its oral C5aR inhibitor, izicopan, across multiple dermatologic and critical care indications. Despite recent clinical setbacks, InflaRx continues to explore the therapeutic potential of its complement platform in life-threatening and debilitating inflammatory conditions.
View full company profileAbout InflaRx
InflaRx is a clinical-stage biopharma focused on selectively inhibiting the C5a/C5aR pathway of the complement system, a key driver of inflammatory diseases. The company achieved a significant milestone with the FDA EUA for vilobelimab in severe COVID-19 and is developing this candidate and its oral C5aR inhibitor, izicopan, across multiple dermatologic and critical care indications. Despite recent clinical setbacks, InflaRx continues to explore the therapeutic potential of its complement platform in life-threatening and debilitating inflammatory conditions.
View full company profileTherapeutic Areas
Other Hidradenitis Suppurativa Drugs
| Drug | Company | Phase |
|---|---|---|
| Tibulizumab (ZB-106) | Zura Bio | Phase 2 |